Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer

Inclusion Criteria: * Female patients with age between 18 and 70 years. * Newly diagnosed breast cancer, stages IIb-IIIc. * KPS performance status≥70. * Measurable disease according to RECIST version 1.1. * Normal cardiac function confirmed by baseline left ventricular ejection fraction (LVEF)≥50%. * Adequate bone marrow reserve (WBC≥4.0×10(9)/L, neutrophils≥2.0×10(9)/L, platelets≥100×10(9)/L,and hemoglobin≥90g/L). * Adequate hepatic and renal function. * AST and ALT ≤ 2×institutional upper limit of normal；alkaline phosphatase ≤ 2×institutional upper limit of normal；bilirubin ≤ institutional upper limit of normal. * Serum creatinine≥44 µmol/L and ≤133 µmol/L. * Written informed consent are acquired. * Not in pregnancy or the pregnancy tests of females is negative. Exclusion Criteria: * Severe heart failure (NYHA grade II or higher). * Active and uncontrolled severe infection. * Have accepted any other anti-tumor drug within 30 days before the first dose or * received radiation treatment. * Other situations that investigators consider as contra-indication for this study.